Sinclair Pharma posts jump in half-year revenues

Sinclair Pharma, whose healthcare products unit was purchased by Alliance Pharma last year, reported a jump in revenue for the six months ended 30 June.

Revenues rose to £17.2m from £7.7m in the first interim period, which was hit by planned destocking.

Silhouette, the company’s skin lifting and repositioning product, saw sales nearly double to £6.1m from £3.2m.

Meanwhile, collagen stimulator Elanse saw revenues grow to £4.2m from £1.7m, with very strong growth across multiple territories and Korea recovering well.

Hyaluronic acid filler Perfectha also performed well, with sales of £3.7m versus £1.3m, reflecting strong growth in Europe, a recovery in Korea and growth in several other markets.

Chief executive Chris Spooner said: “We have made good progress in transforming Sinclair into a leading aesthetics specialist. The business is leaner, simplified and debt free. Revenues have more than doubled in the last six months from a lower cost base, delivering good operating leverage.

“With growth driven by geographical roll-out and line extensions, we are well placed to deliver our promised growth in the short term and remain highly optimistic that the company can deliver strong growth in the medium term."

At 1630 BST, Sinclair shares were up 2.9% to 30.88p.